UY25575A1 - Procedimiento para preparar forma termodinamicamente estable del acido (r)-3-[[(4-fluorofenil)sulfonil]amino]-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban) - Google Patents

Procedimiento para preparar forma termodinamicamente estable del acido (r)-3-[[(4-fluorofenil)sulfonil]amino]-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)

Info

Publication number
UY25575A1
UY25575A1 UY25575A UY25575A UY25575A1 UY 25575 A1 UY25575 A1 UY 25575A1 UY 25575 A UY25575 A UY 25575A UY 25575 A UY25575 A UY 25575A UY 25575 A1 UY25575 A1 UY 25575A1
Authority
UY
Uruguay
Prior art keywords
thermodynamically stable
ramatroban
propanoico
sulfonil
carbazol
Prior art date
Application number
UY25575A
Other languages
English (en)
Inventor
Alfons Grunberg Dr
Karl Heinz Wahl Dr
Klaus - Peter Voges Dr
Original Assignee
Bayer Yakuhin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Yakuhin Ltd filed Critical Bayer Yakuhin Ltd
Publication of UY25575A1 publication Critical patent/UY25575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procedimiento para la preparación de una modificación termodinamicamente estable del compuesto activo ramatroban, mediante la fusión de la forma metaestable y subsiguiente recristalización o sembrando una solución del compuesto activo metaestable con un cristal para sembrar de la forma termodinamicamente estable. El compuesto activo termodinamicamente estable puede ser empleado como un agente para el asma. Una modificación de ramatrobán ha sido descubierta , siendo estable termodinámicamente y estable en su almacenamiento despues del procesamiento por medio de suspensiones y, por lo tanto, es especialmente adecuada para formulaciones farmacéuticas como suspensiones o cremas o granulacion acuosa o trituración en húmedo.
UY25575A 1997-12-24 1999-06-18 Procedimiento para preparar forma termodinamicamente estable del acido (r)-3-[[(4-fluorofenil)sulfonil]amino]-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban) UY25575A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19757983A DE19757983A1 (de) 1997-12-24 1997-12-24 Thermodynamisch stabile Form von (r)-3[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazol-0-propansäure (Ramatroban)
UY25324A UY25324A1 (es) 1997-12-24 1998-12-23 Forma termodinamicamente estable del ácido (r)-3-(((4-fluoro fenil)sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)

Publications (1)

Publication Number Publication Date
UY25575A1 true UY25575A1 (es) 1999-11-17

Family

ID=7853457

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25324A UY25324A1 (es) 1997-12-24 1998-12-23 Forma termodinamicamente estable del ácido (r)-3-(((4-fluoro fenil)sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)
UY25575A UY25575A1 (es) 1997-12-24 1999-06-18 Procedimiento para preparar forma termodinamicamente estable del acido (r)-3-[[(4-fluorofenil)sulfonil]amino]-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY25324A UY25324A1 (es) 1997-12-24 1998-12-23 Forma termodinamicamente estable del ácido (r)-3-(((4-fluoro fenil)sulfonil)amino)-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)

Country Status (37)

Country Link
US (1) US6362214B1 (es)
EP (1) EP1051398B1 (es)
JP (2) JP3817668B2 (es)
KR (1) KR100586350B1 (es)
CN (1) CN1140510C (es)
AR (1) AR013803A1 (es)
AT (1) ATE263152T1 (es)
AU (1) AU744242B2 (es)
BG (1) BG65024B1 (es)
BR (1) BR9814496A (es)
CA (1) CA2313230A1 (es)
CO (1) CO4970800A1 (es)
DE (2) DE19757983A1 (es)
DK (1) DK1051398T3 (es)
ES (1) ES2218874T3 (es)
GT (1) GT199800198A (es)
HK (1) HK1034517A1 (es)
HN (1) HN1998000186A (es)
HU (1) HUP0004432A3 (es)
ID (1) ID25446A (es)
IL (1) IL136278A (es)
IN (1) IN192932B (es)
MY (1) MY116312A (es)
NO (1) NO316618B1 (es)
NZ (1) NZ504741A (es)
PE (1) PE20000115A1 (es)
PL (1) PL341359A1 (es)
PT (1) PT1051398E (es)
RU (1) RU2220137C2 (es)
SI (1) SI1051398T1 (es)
SK (1) SK285109B6 (es)
TR (1) TR200001936T2 (es)
TW (1) TW552258B (es)
UA (1) UA66832C2 (es)
UY (2) UY25324A1 (es)
WO (1) WO1999033803A1 (es)
ZA (1) ZA9811817B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2395120T3 (es) * 2006-12-20 2013-02-08 Cardoz Ab Combinación de pemirolast y ramotrobán para su uso en el tratamiento de transtornos inflamatorios
CA2675520A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
WO2009007674A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and ramatroban or seratrodast
CN101434571B (zh) * 2007-11-13 2012-05-30 杭州容立医药科技有限公司 环烷并[1,2-b]吲哚磺酰胺、其异构体或其盐的合成方法
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
CN103054857A (zh) * 2012-12-30 2013-04-24 北京阜康仁生物制药科技有限公司 一种以雷马曲班为活性成分的固体制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1015711B (zh) 1986-02-21 1992-03-04 拜尔公司 制备环烷并[1，2-b]吲哚-磺酰胺类化合物的方法
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
DE19506739A1 (de) 1995-02-27 1996-08-29 Bayer Ag [3-Amino]-tetrahydrocarbazol-propansäureester

Also Published As

Publication number Publication date
BR9814496A (pt) 2000-10-10
WO1999033803A1 (en) 1999-07-08
RU2220137C2 (ru) 2003-12-27
DE69822882D1 (en) 2004-05-06
ID25446A (id) 2000-10-05
SI1051398T1 (en) 2004-08-31
US6362214B1 (en) 2002-03-26
PT1051398E (pt) 2004-07-30
AR013803A1 (es) 2001-01-10
NZ504741A (en) 2002-10-25
AU1687499A (en) 1999-07-19
NO316618B1 (no) 2004-03-08
KR100586350B1 (ko) 2006-06-07
DE19757983A1 (de) 1999-07-01
CA2313230A1 (en) 1999-07-08
IL136278A0 (en) 2001-05-20
HUP0004432A2 (hu) 2001-06-28
JP4411269B2 (ja) 2010-02-10
BG65024B1 (bg) 2006-12-29
JP2001527067A (ja) 2001-12-25
CO4970800A1 (es) 2000-11-07
TW552258B (en) 2003-09-11
AU744242B2 (en) 2002-02-21
HK1034517A1 (en) 2001-10-26
ATE263152T1 (de) 2004-04-15
SK9752000A3 (en) 2001-02-12
KR20010033529A (ko) 2001-04-25
ES2218874T3 (es) 2004-11-16
DK1051398T3 (da) 2004-07-19
MY116312A (en) 2003-12-31
IN192932B (es) 2004-06-12
JP3817668B2 (ja) 2006-09-06
SK285109B6 (sk) 2006-06-01
CN1282320A (zh) 2001-01-31
DE69822882T2 (de) 2005-02-03
TR200001936T2 (tr) 2001-01-22
HUP0004432A3 (en) 2002-10-28
NO20003217L (no) 2000-06-21
IL136278A (en) 2005-03-20
JP2006151977A (ja) 2006-06-15
PE20000115A1 (es) 2000-03-26
UY25324A1 (es) 2000-12-29
NO20003217D0 (no) 2000-06-21
UA66832C2 (uk) 2004-06-15
EP1051398B1 (en) 2004-03-31
CN1140510C (zh) 2004-03-03
ZA9811817B (en) 1999-06-29
BG104554A (en) 2001-05-31
GT199800198A (es) 1998-12-15
PL341359A1 (en) 2001-04-09
HN1998000186A (es) 1999-11-03
EP1051398A1 (en) 2000-11-15

Similar Documents

Publication Publication Date Title
MX9304611A (es) Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
CU22774A3 (es) Nueva variante cristalina del cdch, procedimiento para su producción y preparados farmacéuticos que la contienen
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
DE3378827D1 (en) Cephalosporin derivatives and process for their preparation
YU88601A (sh) Antifungalna oralna kompozicija koja sadrži itrakonazol i postupak za dobijanje iste
TNSN90003A1 (fr) Derives de 2-aminopyrimidinones utiles notamment comme antagonistes des neurotransmetteurs et procede pour leur preparation
AR015524A1 (es) FORMULACIoN ESTABLE DE SOLUCIoN DE OXIPLATINO, SU USO PARA LA MANUFACTURA DE UN MEDICAMENTO, PROCESO PARA SU PREPARACIoN, PRODUCTO FARMACÉUTICO QUE LA CONTIENE Y UN MÉTODO PARA ESTABILIZAR UNA SOLUCIoN DE OXALIPLATINO.
NO20065078L (no) Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister.
MXPA02001803A (es) Metodos de coformulacion y sus productos.
YU24402A (sh) 2'-supstituisani 1,1'-bifenil-2-karbonamidi, postupak za njihovu proizvodnju, njihova primena kao leka kao i farmaceutski preparati koji sadrže ta jedinjenja
PT801559E (pt) Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
UY25575A1 (es) Procedimiento para preparar forma termodinamicamente estable del acido (r)-3-[[(4-fluorofenil)sulfonil]amino]-1,2,3,4-tetrahidro-9h-carbazol-9-propanoico (ramatroban)
AR006892A1 (es) Uso de formas del acido hialuronico (ha) para el tratamiento del cancer
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them
HK1046902A1 (zh) 新型哌嗪基烷基硫代嘧啶衍生物，包含該衍生物的藥物組合物以及製備該活性物質的方法
PT81229B (pt) Processo para a preparacao de 1,3-dimetil-1h-purino-2,6-dionas contendo 1h-indol-3-ilo e de composicoes farmaceuticas contendo estes compostos
GT200000159A (es) Sal polimorfica.
ATE95185T1 (de) Kristalline cephem saeureadditionssalze und verfahren zu ihrer herstellung.
BR0208828A (pt) Formulação farmacêutica de liberação imediata, processo para a preparação de uma formulação, composição farmacêutica sólida, processo para a formação de uma composição, uso de uma formulação, e, método de profilaxia ou tratamento de uma arritmia
US6538155B1 (en) Method for preparing an EDTA-Tris composition, a composition containing EDTA-Tris and uses therefor
MY101266A (en) Pharmaceutical formulations
CN110755298A (zh) 一种冻干口腔护理组合物及其应用
ES2194899T3 (es) Composicion farmaceutica para administracion transdermica sistemica del principio activo morfina-6-glucuronido.
ES2195925T3 (es) Proceso para fabricar una formulacion de liberacion retardada.